Patent expiry of tirzepatide?

There isn’t a single “patent expiry” for tirzepatide. Tirzepatide is protected by multiple patent families (composition, uses, formulations, methods, etc.) across jurisdictions, plus regulatory exclusivities. Expiry dates vary by country and by patent family, and can be affected by term adjustments and legal challenges.

What you might want to know (and how I can help):
- Jurisdiction-focused expiry: Do you want US, EU, UK, JP, or another country? I can pull the relevant patent family expiry dates from patent databases (Google Patents, Espacenet, USPTO, etc.).
- Types of protection: Do you want only composition-of-matter patents (the core peptide) or also use, formulation, and process patents?
- Regulatory exclusivity: In the US, tirzepatide is a biologic approved in 2022, so there is 12 years of data exclusivity from approval (with possible pediatric extensions), which can delay biosimilar competition even after patents expire. The EU has its own data/market exclusivity framework.

If you want, tell me the jurisdiction(s) and I’ll summarize the current status and provide approximate expiry windows and the key patent families involved.